PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17437547-5	2007	Retigabine-induced inhibition of K+-evoked [3H]DA release was also abolished by synaptosomal entrapment of blocking anti-KCNQ2 polyclonal antibodies, an effect prevented by antibody pre-absorption with the KCNQ2 immunizing peptide.	ezogabine	0-10	potassium voltage-gated channel subfamily Q member 2	Rattus norvegicus	121-126	
28741430-0	2017	Orofacial neuropathic pain induced by oxaliplatin: downregulation of KCNQ2 channels in V2 trigeminal ganglion neurons and treatment by the KCNQ2 channel potentiator retigabine.	ezogabine	165-175	potassium voltage-gated channel subfamily Q member 2	Rattus norvegicus	139-144	
23176257-7	2013	The effect was also apparent in the Retigabine-insensitive mutant KCNQ2-W236L.	ezogabine	36-46	potassium voltage-gated channel subfamily Q member 2	Rattus norvegicus	66-71	
34133772-1	2021	Retigabine (RTG, Ezogabine, DC23129) is the first neuronal potassium channel opener in the treatment of epilepsy and exerts its effects through the activation of neuronal KCNQ2/3 potassium channels, in higher doses, acts also on sodium and voltage-gated calcium channels.	ezogabine	0-10	potassium voltage-gated channel subfamily Q member 2	Rattus norvegicus	171-178	
34133772-1	2021	Retigabine (RTG, Ezogabine, DC23129) is the first neuronal potassium channel opener in the treatment of epilepsy and exerts its effects through the activation of neuronal KCNQ2/3 potassium channels, in higher doses, acts also on sodium and voltage-gated calcium channels.	ezogabine	12-15	potassium voltage-gated channel subfamily Q member 2	Rattus norvegicus	171-178	
34133772-1	2021	Retigabine (RTG, Ezogabine, DC23129) is the first neuronal potassium channel opener in the treatment of epilepsy and exerts its effects through the activation of neuronal KCNQ2/3 potassium channels, in higher doses, acts also on sodium and voltage-gated calcium channels.	ezogabine	17-26	potassium voltage-gated channel subfamily Q member 2	Rattus norvegicus	171-178	
17437547-5	2007	Retigabine-induced inhibition of K+-evoked [3H]DA release was also abolished by synaptosomal entrapment of blocking anti-KCNQ2 polyclonal antibodies, an effect prevented by antibody pre-absorption with the KCNQ2 immunizing peptide.	ezogabine	0-10	potassium voltage-gated channel subfamily Q member 2	Rattus norvegicus	206-211	
10953053-0	2000	Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels.	ezogabine	0-10	potassium voltage-gated channel subfamily Q member 2	Rattus norvegicus	60-65	
16362775-2	2005	Retigabine is an opener of the KCNQ2/Q3-type K+ channel that possesses antiepileptic action and may be neuroprotective, and we have therefore studied its effect on the hyperexcitation, the neuronal damage and the changes in extracellular glutamate induced by 4-AP.	ezogabine	0-10	potassium voltage-gated channel subfamily Q member 2	Rattus norvegicus	31-36	
10953053-6	2000	Retigabine-induced currents in CHO-KCNQ2/Q3 cells were inhibited by 60.6 +/- 11% (n = 4) by the KCNQ2/Q3 blocker, linopirdine (10 microM), and 82.7 +/- 5.4% (n = 4) by BaCl(2) (10 mM).	ezogabine	0-10	potassium voltage-gated channel subfamily Q member 2	Rattus norvegicus	35-40	
10953053-6	2000	Retigabine-induced currents in CHO-KCNQ2/Q3 cells were inhibited by 60.6 +/- 11% (n = 4) by the KCNQ2/Q3 blocker, linopirdine (10 microM), and 82.7 +/- 5.4% (n = 4) by BaCl(2) (10 mM).	ezogabine	0-10	potassium voltage-gated channel subfamily Q member 2	Rattus norvegicus	96-101	
10953053-7	2000	The mechanism by which retigabine enhanced KCNQ2/Q3 currents involved large, drug-induced, leftward shifts in the voltage dependence of channel activation (-33.1 +/- 2.6 mV, n = 4, by 10 microM retigabine).	ezogabine	23-33	potassium voltage-gated channel subfamily Q member 2	Rattus norvegicus	43-48	
10953053-7	2000	The mechanism by which retigabine enhanced KCNQ2/Q3 currents involved large, drug-induced, leftward shifts in the voltage dependence of channel activation (-33.1 +/- 2.6 mV, n = 4, by 10 microM retigabine).	ezogabine	194-204	potassium voltage-gated channel subfamily Q member 2	Rattus norvegicus	43-48	
10953053-10	2000	Our findings identify KCNQ2/Q3 channels as a molecular target for retigabine and suggest that activation of KCNQ2/Q3 channels may be responsible for at least some of the anticonvulsant activity of this agent.	ezogabine	66-76	potassium voltage-gated channel subfamily Q member 2	Rattus norvegicus	22-27